Drug Profile
CKD 902
Alternative Names: CKD902Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antineoplastics; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Benign-prostatic-hyperplasia in South Korea
- 15 Dec 2015 Phase-I clinical trials in Benign prostatic hyperplasia in South Korea (unspecified route) prior to December 2015 (Chong Kun Dang pipeline, December 2015)